ASCO 2017 - Acute Myeloid Leukemia

Although two-thirds of patients with newly diagnosed acute myeloid leukemia (AML) are tested for recurrent mutations, most do not receive the complete panel of guideline-recommended tests.

The majority of newly diagnosed patients with acute myeloid leukemia (AML) were found to be minimal residual disease (MRD)-negative after induction with a crenolanib-containing regimen.

Differentiation syndrome, a side effect of enasidenib therapy, can often be managed with pharmacologic interventions and, if necessary, dose interruption.

Patients with acute myeloid leukemia (AML) and TP53 mutations may benefit from certain types of low-intensity chemotherapy.

In a phase 1 study, the mIDH2 inhibitor enasidenib showed promise as a potential emerging therapy for patients with relapsed or refractory acute myeloid leukemia (AML).

Synthetic control arms may represent an efficient, cost-effective way to evaluate early end points in clinical trials.

Building on the results of a prior study, the combination of sorafenib and 5-azacytidine demonstrates promise in the treatment of older patients with FLT3-ITD–positive acute myeloid leukemia.

In this analysis, minimal residual disease (MRD)-negative status in patients with acute myeloid leukemia (AML) translated into lower risk of relapse but not improved relapse-free survival or overall survival.

A recent analysis suggests that molecular response to gilteritinib may correlate with clinical response and improved overall survival.

Specific types of somatic mutations predicted improved relapse-free survival in patients with acute myeloid leukemia (AML) achieving complete remission.

Page 1 of 2
Results 1 - 10 of 16
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME